GH Guardant Health, Inc. Insider Trading

CLO John G. Saia sold 10,000 shares at $125.08 blended average, reducing holdings 21.8% via scheduled 10b5-1 plan.

John G. Saia, Chief Legal Officer at Guardant Health, executed 2 separate sales totaling 10,000 shares for $1,250,835.98 on 2026-05-27 under a pre-arranged 10b5-1 trading plan. The sale reduced his holdings from 45,950 shares to 35,950 shares (a 21.8% reduction). This transaction is scheduled under a 10b5-1 plan, not a discretionary decision, so it reflects plan timing rather than active strategic positioning. Guardant Health trades at $133.22 currently, above the 52-week high of $128.00 and up 60.3% over 30 days and 41.9% over 90 days, while the company posted negative net income of $-112,075,000.00 despite revenue growth of 32.9% annually.

CCO Chris Freeman sells 24.4K GH shares at $118.67; holds 60.0K remaining after -28.9% reduction.

Chris Freeman, Chief Commercial Officer of Guardant Health, sold 24,406 shares for $2.9M on 2026-05-22 at $118.67 per share, reducing his non-derivative holdings by 28.9% to 60,034 shares; he retains 701 shares in option form. The sale occurs at a price 1.0% below the 52-week high of $121.01, with the stock up 34.8% over the prior 30 days and 25.8% over 90 days—a period of substantial appreciation. Notably, across his prior five trades in Guardant Health all executed on 2025-12-05, Freeman achieved a 100% well-timed rate at the 90-day horizon, with all subsequent holdings declining 8.7% to 13.2%, and his cross-ticker track record shows a 100.00% 90-day well-timed rate across 11 prior sells with an average 90-day return of -10.8%. The company remains unprofitable (net income of -$112.1M in the latest quarter) despite solid revenue growth of 32.9% year-over-year and a $15.9B market cap, creating a backdrop where an insider with a demonstrated pattern of selling before subsequent declines is now liquidating a material stake at elevated valuations.

GH CLO John G. Saia sells 20,000 shares for $2.1M via 10b5-1 plan; current price $118.95 vs $106.51 blended sale price

Chief Legal Officer John G. Saia executed 3 separate sales totaling 20,000 shares for $2,130,228.98 on 2026-05-20 at prices ranging from $105.34 to $107.23, under a pre-arranged 10b5-1 trading plan. As scheduled trades, these sales do not reflect discretionary timing decisions by the insider. His post-transaction holdings stand at 45,950 shares, representing a -30.3% reduction versus pre-transaction holdings of 65,950 shares. The company is unprofitable with net income of $-112,075,000.00 over its most recent full fiscal year, though revenue reached $301,665,000.00 and grew +32.9% year-over-year, indicating expansion amid ongoing losses.

Co-CEO Amirali Talasaz sells 210,000 shares (10% of holdings) for $23.1M via 12 scheduled transactions at GH

Amirali Talasaz executed 12 separate sales totaling 210,000 shares for $23,076,690.06 on 2026-05-20 via a pre-arranged 10b5-1 trading plan, reducing his holdings from 2,096,504 to 1,886,504 shares. This scheduled transaction occurred while the stock was up +32.8% over the prior 30 days and +15.4% over 90 days, trading at $118.95 versus the blended sale price of $109.89. The company remains unprofitable on an annual basis (net income $-112,075,000.00 for the most recent full fiscal year) despite strong revenue growth of +32.9% year-over-year and a market cap of $15.8B. Since this sale is part of a pre-arranged plan rather than a discretionary decision, it reflects scheduled portfolio actions rather than reactive decision-making tied to current market conditions.

Co-CEO Talasaz Amirali sold 50,000 shares for $5M; 6th sale at GH in 36 months with prior sells poorly timed at 30 days but well-timed at 90 days.

Talasaz Amirali, Co-Chief Executive Officer of Guardant Health, sold 50,000 shares valued at $5 million, reducing his indirect stake by that amount. This is the sixth open-market sale at the company within the past three years, part of a consistent pattern of dispositions with no offsetting open-market purchases in that window. Examining his prior sales at Guardant, the outcomes present a conflicting picture: all five earlier exits proved poorly timed in the short term as the stock gained in the following month, yet all five were well-timed over a longer three-month horizon as the stock subsequently fell. The company remains unprofitable on an annual basis despite posting revenue growth above 30 percent year-over-year, and the stock currently trades significantly below its 52-week high. This sale occurs against a backdrop where the insider has a long track record of selling but no recent open-market buying activity, suggesting steady position reductions rather than active portfolio management around company catalysts.